Literature DB >> 26161469

Beneficial Effects of Long-Term Growth Hormone Treatment on Adaptive Functioning in Infants With Prader-Willi Syndrome.

Sin T Lo, Dederieke A M Festen, Roderick F A Tummers-de Lind van Wijngaarden, Philippe J L Collin, Anita C S Hokken-Koelega.   

Abstract

The aim of this study was to investigate the effect of growth hormone treatment on adaptive functioning in children with Prader-Willi syndrome. Vineland Adaptive Behavior Scale (VABS) was assessed during a randomized controlled trial (RCT) and after 7 years of growth hormone treatment. In the RCT, 75 children (42 infants and 33 prepubertal children) with Prader-Willi syndrome were included. Subsequently, 53 children were treated with long-term growth hormone. Our study demonstrates a marked delay in adaptive functioning in infants and children with Prader-Willi syndrome, which was associated with older age and lower intelligence. Results of the repeated measurements show that the earlier growth hormone treatment was started during infancy, the better the adaptive skills were on the long-term.

Entities:  

Keywords:  Prader-Willi syndrome; adaptive functioning; growth hormone

Mesh：

Substances：

Year:  2015        PMID： 26161469     DOI： 10.1352/1944-7558-120.4.315

Source DB:  PubMed          Journal:  Am J Intellect Dev Disabil        ISSN： 1944-7558


  13 in total

1.  Cognitive and adaptive advantages of growth hormone treatment in children with Prader-Willi syndrome.

Authors:  Elisabeth M Dykens; Elizabeth Roof; Hailee Hunt-Hawkins
Journal:  J Child Psychol Psychiatry       Date:  2016-08-02       Impact factor: 8.982

2.  Impact of genetic subtypes of Prader-Willi syndrome with growth hormone therapy on intelligence and body mass index.

Authors:  Merlin G Butler; Naomi A Matthews; Nidhi Patel; Abhilasha Surampalli; June-Anne Gold; Manaswitha Khare; Travis Thompson; Suzanne B Cassidy; Virginia E Kimonis
Journal:  Am J Med Genet A       Date:  2019-07-16       Impact factor: 2.802

3.  Aberrant White Matter Microstructure in Children and Adolescents With the Subtype of Prader-Willi Syndrome at High Risk for Psychosis.

Authors:  Akvile Lukoshe; Gerbrich E van den Bosch; Aad van der Lugt; Steven A Kushner; Anita C Hokken-Koelega; Tonya White
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

4.  A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.

Authors:  Laura Greiss Hess; Sarah E Fitzpatrick; Danh V Nguyen; Yanjun Chen; Kimberly N Gaul; Andrea Schneider; Kerrie Lemons Chitwood; Marwa Abd Al Azaim Eldeeb; Jonathan Polussa; David Hessl; Susan Rivera; Randi J Hagerman
Journal:  J Dev Behav Pediatr       Date:  2016-10       Impact factor: 2.225

Review 5.  A cross-comparison of cognitive ability across 8 genomic disorders.

Authors:  Michael Mortillo; Jennifer G Mulle
Journal:  Curr Opin Genet Dev       Date:  2021-05-31       Impact factor: 4.665

6.  Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial.

Authors:  R J Kuppens; E F Mahabier; N E Bakker; E P C Siemensma; S H Donze; A C S Hokken-Koelega
Journal:  Orphanet J Rare Dis       Date:  2016-11-16       Impact factor: 4.123

7.  Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition.

Authors:  Layla Damen; Stephany H Donze; Renske J Kuppens; Nienke E Bakker; Laura C G de Graaff; Janielle A E M van der Velden; Anita C S Hokken-Koelega
Journal:  Orphanet J Rare Dis       Date:  2020-06-24       Impact factor: 4.123

8.  A multidisciplinary approach to the clinical management of Prader-Willi syndrome.

Authors:  Jessica Duis; Pieter J van Wattum; Ann Scheimann; Parisa Salehi; Elly Brokamp; Laura Fairbrother; Anna Childers; Althea Robinson Shelton; Nathan C Bingham; Ashley H Shoemaker; Jennifer L Miller
Journal:  Mol Genet Genomic Med       Date:  2019-01-29       Impact factor: 2.183

9.  Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial.

Authors:  Aram Yang; Jin-Ho Choi; Young Bae Sohn; Yunae Eom; Jiyoon Lee; Han-Wook Yoo; Dong-Kyu Jin
Journal:  Orphanet J Rare Dis       Date:  2019-09-11       Impact factor: 4.123

10.  Growth hormone treatment in Prader-Willi syndrome patients: systematic review and meta-analysis.

Authors:  Caroline de Gouveia Buff Passone; Ruth Rocha Franco; Simone Sakura Ito; Evelinda Trindade; Michel Polak; Durval Damiani; Wanderley Marques Bernardo
Journal:  BMJ Paediatr Open       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.